Skip to Content
Merck
  • Enhanced degradation of cathepsin D synthesized in the presence of the threonine analog beta-hydroxynorvaline.

Enhanced degradation of cathepsin D synthesized in the presence of the threonine analog beta-hydroxynorvaline.

Archives of biochemistry and biophysics (1984-04-01)
M Hentze, A Hasilik, K von Figura
ABSTRACT

The threonine analog beta-hydroxynorvaline is an inhibitor of asparagine-linked glycosylation. In the presence of the analog human fibroblasts synthesized cathepsin D molecules containing two, one, or no oligosaccharides. The nonglycosylated cathepsin D precursor was but a minor species and was degraded within 45 min of its synthesis, presumably in the lumen of the endoplasmic reticulum. The polypeptides with one or two oligosaccharides were normally segregated into lysosomes and their proteolytic maturation was not affected. The stability of mature glycosylated and nonglycosylated cathepsin D polypeptides within the lysosomes, however, was markedly decreased. The recovery of cathepsin D polypeptides was increased in the presence of inhibitors of cysteine and aspartyl-proteinases. These data suggest that the absence of carbohydrate side chains in cathepsin D results in an enhancement of the degradation rate of the precursor in the endoplasmic reticulum, and the replacement of threonine by beta-hydroxynorvaline in an enhanced degradation of the mature cathepsin D in lysosomes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-3-Hydroxynorvaline, ≥98% (TLC)